Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.
Avance Clinical is an Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 24 years.
Frost & Sullivan says the Asia-Pacific’s CRO market value, currently at $6.01 billion, is estimated to reach nearly $11.04 billion in 2026, growing at a compound annual rate of 12.2%.
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical has won the Fast MoversSAExcellence in Business Award 2021 sponsored by international accounting and business advisory firm BDO.
According to BDO the Fast Movers SA Excellence in Business Award, recognises a company that has achieved exceptional and sustained growth year on year, and demonstrates innovative strategies and market leadership, as shown by leading CRO Avance Clinical.
“BDO is proud to be involved with an awards program that recognises South Australia’s fastest growing, most innovative and arguably smartest businesses. Avance Clinical CEO Yvonne Lungershausen and her team focus on providing quality services while maintaining a global perspective but also a local South Australian focus – particularly as an employer of choice, making them a worthy winner of this award,” says Rudy Pieck, Managing Partner, BDO South Australia.
Avance Clinical CEO Yvonne Lungershausen, said
“As the Australian CRO for biotechs we are very pleased to be recognised for our business excellence,” she said.
“The Fast Movers Excellence in Business Award is recognition of the quality work conducted by Avance Clinical, and how we manage our growth trajectory as we continue to attract biotechs from around the world for clinical research services.
It really is all about our staff and how we support and nurture them with a team environment, training, and career progression and, most importantly, the time and resources to deliver the very best for our clients.
Australia is highly regarded around the globe for quality clinical research, rapid start-up, and the world’s most attractive rebate of 43.5% on clinical trial spend.
Biotechs from the US, Asia and EU are discovering the enormous benefits of conducting their clinical research in Australia and, perhaps most importantly, that our clinical data is accepted by all the major international regulatory authorities.”
The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).
This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).
In Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology Act 2000. The OGTR administers the Gene Technology Act 2000, and has specific responsibility to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating dealings with GMOs.
The global market for genetic modification therapies is expected to grow from $2.3 billion in 2018 to reach $17.4 billion by 2023, growing at a compound annual growth rate of 49.9% (BCC Research, 2018). The utilization of gene modification technologies used in COVID-19 vaccine products is likely to translate in further growth in this field of therapeutics.
Avance Clinical CEO Yvonne Lungershausen, said OGTR accreditation is important for our international clients. “Our clients need to know that their CRO has all the necessary credentials and is capable of delivering the highest of clinical research standards in this exciting and rapidly evolving sector,” she said.
Avance Clinical currently has a number of GMO studies underway and is expanding its services further to accommodate increasing global demand.
Avance Clinical has positioned itself as a global leader in early phase clinical trials by developing innovative strategies and approaches to initial phase development. It helps global biotech companies set up clinic and achieve proof of concept faster with a data package that stands up to the scrutiny of global regulators. The company is well reputed for proven support of the biotech industry by providing scientific and regulatory expertise to help develop the best strategy to achieve clinical trial outcomes in the most time- efficient manner. Read the full report here.
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.
Avance Clinical made the announcement today at AusBiotech 2020 (28 – 30 October, 2020).
Avance Clinical CEO Yvonne Lungershausen said the company was very pleased to be awarded such recognition by MasterControl, a leader in the clinical digital management technology.
“The award acknowledges our leadership as Australia’s biotech CRO and it provides further confidence to our clients that we are serious about delivering quality clinical research services by being nimble and adaptive, and by utilising state-of-the-art systems that are compliant with industry standards, such as MasterControl eQMS,” said Yvonne Lungershausen.
“Avance Clinical invests significantly in the industry’s leading clinical technologies making it one of the most advanced CROs globally for digital clinical research management and eClinical solutions.”
On presenting the Innovation Excellence Award, MasterControl said the award recognises “the power of innovation and celebrates companies who feel the same way we do, who are not afraid to shed the status quo to find their own path and who push boundaries and spearhead important changes within their industries. Companies driven by innovation who truly live and breathe it.”
Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
“Receiving the award from MasterControl is a testament of our commitment to invest in our Quality Management System and to continually improve and strengthen it. This Award recognises and provides visibility to our efforts to push boundaries and adopt this significant change not just for the Quality Assurance department but across-the-board in the organisation.”
“MasterControl eQMS enables accurate, streamlined processes for Document Control and Training. Avance Clinical, which is on a significant growth trajectory, requires robust procedures as part of our QMS. MasterControl has allowed our staff to create/review and access our controlled documents in real-time and the automated link between different modules enables timely delivery of training.”
Avance Clinical Director Compliance and Training, Lisa Eglinton said:
“MasterControl Training Module provides a robust, user-friendly method for the delivery of role-specific training programs to all staff. The system provides a real-time indication of training status to Trainees and their Line Managers which ensures training compliance across the company.”
Avance Clinical is the leading Australian owned CRO that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
(From left to right) Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical’s CEO, and Lisa Eglinton, Director Compliance and Training.
As a major sponsor, Soniclean is thrilled to be able to celebrate South Australian exporting excellence by sponsoring the International Health Award and its recognition of Avance Clinical, which progresses to the national final in Canberra on 3 December.
The Business SA 2019 Export Awards recognise South Australian companies which are excelling in the international marketplace by selling and promoting their products and services, including our award’s winner, Avance Clinical.
Announced at a gala ceremony at the Adelaide Convention Centre last night, Avance Clinical was recognised as providing world-class clinical research services to the local and international drug development industry, with clients across North America, Canada, New Zealand, Europe and Asia.
Avance Clinical assists its clients in conducting and reporting of clinical trial data to ensure they meet their drug development timelines.
Now in their 57th year, the Business SA Export Awards recognise local businesses breaking into export markets and achieving sales, organisational and educational growth.
The coveted Business SA 2019 South Australian Exporter of the Year Award went to aquaculture business Clean Seas Seafood, as this year’s most outstanding exporting business. Accolade Wines was presented with the Statewide Excellence in Exporting Award, recognising international impact.
Other major award winners included Redarc Electronics, the University of Adelaide, Rising Sun Pictures, Monkeystack, Zonge Engineering and Research Organisation, Wines by Geoff Hardy, Haselgrove Wines, Sentek, Prophecy International Holdings, Mollydooker Wines and Supashock.
Soniclean is among the world’s foremost manufacturers of innovative medical-grade ultrasonic cleaners, with more than two decades of leadership experience in the ultrasonic industry. Soniclean ultrasonic cleaners provide a faster, safer alternative to conventional cleaning methods.
Having a strong export market is critical to growing South Australia’s economy, and Soniclean, along with Avance Clinical, are ensuring our state goes from strength to strength.
For further details or to arrange an interview, please contact: Business SA Director of Media and Communications, Verity Edwards on 0412 678 942 Soniclean Chief Executive Officer, Robyn Lee on 08 8234 8398 Avance Clinical Chief Executive, Yvonne Lungerhausen on 8159 6388
Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Awardat a global virtual awards ceremony overnight.
According to Frost & Sullivan:
“The Frost & Sullivan Best Practices awards have identified and honored best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.”
This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.
Avance Clinical CEO Yvonne Lungershausen commended her team of more than 100 clinical trial specialists throughout Australia and New Zealand.
“We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.”
“Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials.”
“Avance Clinical are experts in facilitating fast study start up with trials typically approved and initiated in under 6 weeks.”
Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
Avance specialises in supporting biotech companies with their early phase clinical trials having conducted over 150 early phase (Phase 1 and 2) trials in the past 4 years involving treatment of over 8,300 participants across 95 therapeutic indications.
According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:
“Within Asia-Pacific’s highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. The company offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance.
Avance Clinical is a full service CRO with a 20-year track-record.
The company has grown quickly over the past year doubling staff numbers and with plans to further expand in the region. Avance Clinical offers a real size match for biotechs that means better mission understandings and stronger customer service compared to some of the larger CROs.
Avance’s reputation for high-quality clinical trial outcomes leveraging its scientific and regulatory expertise has attracted an impressive 74% repeat business rate, underscoring the company’s position as a market leader.”
In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high quality sites and attractive cost of running trials in Australia including:
The Australian Government financial rebate of up to 43.5% on clinical trial spend
No IND required for clinical trials and streamlined regulatory processes
Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities
Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.
The Frost & Sullivan Best Practices awards have identified and honored best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.
For the Market Leadership Award, Frost & Sullivan analysts independently elucidated the following key benchmarking criteria:
1. Technology Leverage
2. Customer Purchase Experience
3. Price/Performance Value
4. Growth Strategy Excellence
5. Customer Service Experience
6. Brand Strength
With its strong overall performance, Avance Clinical Pty Ltd has earned the 2020 Asia-Pacific CRO Market Leadership Award. We also recognize that your receipt of this award is the result of many individuals (employees, customers and investors) making daily choices to believe in the organization and contribute in a meaningful way to its future.
Monday to Friday: 8.00 am to 5.30 pm
Avance Clinical is a full-service CRO that leverages the entire suite of eClinical technology, and an expert team of more than 150 CRO specialists, to deliver clinical drug development services for international biotechs.
The largest Australian CRO for international biotechs
Avance Clinical is the largest specialist Australian CRO delivering quality clinical trials in Australia and New Zealand for international biotechs for the past 24 years.